Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs everolimus in previously treated advanced clear-cell renal cell carcinoma
2011-005132-26Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: overall survival. Started Jul 2012; status: completed.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2011-005132-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005132-26.